What Is CagriSema? The Cagrilintide + Semaglutide Combination Explained

CagriSema cagrilintide semaglutide combination amylin GLP-1 research Durham Peptides Canada

CagriSema is one of the most closely watched investigational compounds in modern metabolic research — and one of the clearest examples of where the field is heading. Rather than refining a single incretin pathway, it combines two different mechanisms in one fixed-dose formulation: an amylin analog (cagrilintide) and a GLP-1 receptor agonist (semaglutide). The result is a combination studied for additive or synergistic metabolic effects, currently progressing through Phase 3 clinical trials and the subject of a major published readout.

This article explains what CagriSema is, what each component contributes, what the published clinical data shows, and where it fits relative to other next-generation metabolic compounds. For Canadian researchers, Durham Peptides supplies the CagriSema Blend (Cagrilintide 5mg + Semaglutide 5mg). Nothing here is medical, dosing, or therapeutic guidance.

What "CagriSema" Actually Means

"CagriSema" is the research designation for a fixed-dose combination of two synthetic peptides — cagrilintide and semaglutide — originally developed by Novo Nordisk. The name is a simple contraction of the two components. It isn't a new single molecule; it's two well-characterized peptides studied together in one formulation, each acting on a different receptor system.

This makes CagriSema conceptually similar to the dual- and triple-agonist approach in the rest of the metabolic peptide field — combining mechanisms to exceed what any single pathway achieves — but with a distinct twist: rather than building one molecule that hits multiple receptors (the tirzepatide and retatrutide approach), it pairs two separate molecules. For the single-molecule multi-agonist story, see Triple Agonist Peptides Explained.

Component 1: Cagrilintide — the Amylin Analog

Cagrilintide is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. Its key identity data:

• CAS number: 1415456-99-3

• Molecular weight: ~3,706 g/mol

• Class: long-acting amylin / calcitonin receptor agonist

Amylin works through a different system than the incretins. It acts on amylin and calcitonin receptors, with effects studied in brainstem satiety pathways, gastric emptying, and glucagon regulation. Because amylin signaling is mechanistically separate from GLP-1 signaling, cagrilintide brings a non-redundant pathway to the combination — which is the entire rationale for pairing it with semaglutide.

Component 2: Semaglutide — the GLP-1 Receptor Agonist

Semaglutide is the foundational GLP-1 receptor agonist and the most extensively studied incretin peptide. Its key identity data:

• CAS number: 910463-68-2

• Molecular weight: 4,113.6 g/mol

• Class: GLP-1 receptor agonist

Semaglutide acts on the GLP-1 receptor, with effects studied in hypothalamic appetite suppression, glucose-dependent insulin secretion, gastric emptying, and glucagon regulation. It's the reference compound the entire incretin field is measured against — see What Is Semaglutide? The GLP-1 Peptide Reshaping Metabolic Research for the full background.

Why Combine Amylin and GLP-1?

The CagriSema rationale rests on the same principle as every successful metabolic combination: pair mechanisms that are complementary rather than redundant. Cagrilintide (amylin pathway) and semaglutide (GLP-1 pathway) act on different receptor systems and influence satiety and metabolism through partially distinct routes:

• Cagrilintide / amylin: brainstem satiety signaling, gastric emptying delay, glucagon suppression

• Semaglutide / GLP-1: hypothalamic appetite suppression, glucose-dependent insulin secretion

Engaging both systems at once is studied for a combined effect greater than either component alone — and, importantly, the published Phase 3 data supports that this combination effect is real. This contrasts with the single-molecule multi-agonist designs (tirzepatide, retatrutide), making CagriSema a distinct strategic branch of metabolic peptide research. For the full side-by-side, see CagriSema vs Tirzepatide vs Retatrutide.

The Clinical Trial Program

CagriSema is among the most advanced investigational metabolic combinations, currently progressing through a Phase 3 program that includes the REDEFINE 1, REDEFINE 2, and

REIMAGINE 2 trials. The published Phase 3 data in the New England Journal of

Medicine (2025) reported a mean body-weight reduction of 20.4% in the combination arm versus 3.0% with placebo over 68 weeks — a magnitude that places it among the most effective investigational metabolic combinations studied to date.

For researchers, the unusually mature clinical evidence base is part of what makes CagriSema an interesting reference compound: unlike many research peptides where preclinical enthusiasm runs ahead of human data, CagriSema has substantial published human trial results to anchor research context.

What Researchers Examine

In CagriSema research, common areas of investigation include:

• Cagrilintide: amylin and calcitonin receptor activation, brainstem satiety pathways

• Semaglutide: GLP-1 receptor agonism, hypothalamic appetite suppression

• Combined versus monotherapy comparisons across Phase 1–3 clinical data

• Glucagon suppression and gastric-emptying delay (cagrilintide) versus insulin-secretion modulation (semaglutide)

• Weight-loss curves, lipid parameters, and cardiometabolic markers in published trials

The Blend Format and Quality Standards

Durham Peptides' CagriSema Blend contains 5mg cagrilintide + 5mg semaglutide (10mg total, 1:1 ratio). Both components feature fatty-acid lipidation supporting the extended, once-weekly-style half-life profile studied in the trials.

As a blend, per-component verification matters: the COA should confirm both peptides are present, identified by mass spectrometry, and meet the purity threshold. Durham Peptides' blend is Janoshik-verified to ≥99% purity per componentwith MS identity for both, on an independently verifiable COA. For how to read those documents, see How to Read a Janoshik COA and the Lab Results page. Both components co-reconstitute in bacteriostatic water; use the peptide calculator for volume math.

Frequently Asked Questions

What is CagriSema? A fixed-dose research combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), studied for combined amylin/GLP-1 metabolic effects and currently in Phase 3 trials.

What does CagriSema stand for? It's a contraction of its two components: Cagrilintide + Semaglutide.

Is CagriSema one molecule or two? Two. Unlike tirzepatide or retatrutide (single molecules hitting multiple receptors), CagriSema pairs two separate peptides in one formulation.

What is cagrilintide? A long-acting amylin analog that acts on amylin and calcitonin receptors, studied in brainstem satiety, gastric emptying, and glucagon-regulation pathways.

What did the CagriSema trials show? Published Phase 3 data in NEJM (2025) reported a 20.4% mean body-weight reduction in the combination arm versus 3.0% with placebo over 68 weeks.

Where can I buy CagriSema in Canada? Durham Peptides supplies the CagriSema Blend for laboratory use only, Janoshik-verified per component. See Buy CagriSema in Canada.

Final Thoughts

CagriSema represents a distinct and increasingly important branch of metabolic peptide research: the pairing of two separate, complementary peptides — amylin and GLP-1 — rather than engineering one molecule to do everything. With a mature Phase 3 evidence base behind it, including a headline NEJM readout, it's one of the most data-anchored compounds in the category.

For Canadian researchers, Durham Peptides supplies the CagriSema Blend at C$145.00. For the comparison to single-molecule multi-agonists, see CagriSema vs Tirzepatide vs Retatrutide; for the buying decision, see Buy CagriSema in Canada.

Selected Research References

1. Garvey WT, Blüher M, Kushner RF, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/40548661/

2. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Concomitant Administration of Multiple Doses of Cagrilintide with Semaglutide 2·4 mg. The Lancet. 2021;397(10286):1736-1748. https://pubmed.ncbi.nlm.nih.gov/33894838/

3. Frías JP, Deenadayalan S, Erichsen L, et al. Efficacy and Safety of Co-administered Once-Weekly Cagrilintide and Semaglutide in Adults with Type 2 Diabetes. The Lancet. 2023;402(10403):720-730. https://pubmed.ncbi.nlm.nih.gov/37364590/

4. Lau DCW, Erichsen L, Francisco AM, et al. Once-Weekly Cagrilintide for Weight Management in People with Overweight and Obesity. The Lancet. 2021;398(10317):2160-2172. https://pubmed.ncbi.nlm.nih.gov/34798060/

All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.